Irinotecan
Metastasis From Malignant Tumor Of Colon
Floatz Rating
BB68/100
Confidence
Indicative
Sponsor
Jun Huang
Modality
Small molecule
Development Phase
Phase 3
Status
Active
Evidence ledger · v0.2
Clinical Evidence
Clinical track record: trial progression, reported outcomes, safety signals, and endpoint quality.
58High confidence
Detailed axis rationale is planned and will be published soon.
| Trial | Phase | Status | N | Primary endpoint | Readout |
|---|---|---|---|---|---|
NCT07381309CT.gov Oncolytic Virus (H101) + SBRT + Chemotherapy + Targeted Therapy + Immunotherapy for Unresectable CRLM | — | Not Yet Recruiting | — | — | — |
NCT07441369CT.gov Abemaciclib Combined With FOLFOX/FOLFIRI Regimen in Patients With Advanced Colorectal Liver Metastases Cancer | — | Enrolling By Invitation | — | — | — |
NCT06788171CT.gov PULSAR Combined With PD-1 Ab and Chemotherapy Plus Bev. for CRLM | — | Not Yet Recruiting | — | — | — |
NCT06199232CT.gov Targeted Treatment Plus Tislelizumab and HAIC for Advanced CRCLM Failed From Standard Systemic Treatment | — | Active Not Recruiting | — | — | — |
NCT05983367CT.gov A Study to Investigate Ompenaclid Combined With FOLFIRI Plus Bevacizumab in Advanced/Metastatic Colorectal Cancer | — | Terminated | — | — | — |
NCT05848739CT.gov A Phase 1-2 of ST316 With Selected Advanced Unresectable and Metastatic Solid Tumors | — | Recruiting | — | — | — |
NCT05861505CT.gov COLLISION RELAPSE Trial | — | Recruiting | — | — | — |
NCT04595266CT.gov Chemoembolization (Lifepearls-Irinotecan) in Patients With Colorectal Cancer and Metastatic Disease | — | Active Not Recruiting | — | — | — |
NCT03203525CT.gov Combination Chemotherapy and Bevacizumab With the NovoTTF-100L(P) System in Treating Participants With Advanced, Recurrent, or Refractory Hepatic Metastatic Cancer | — | Active Not Recruiting | — | — | — |
NCT03803553CT.gov Identification and Treatment Of Micrometastatic Disease in Stage III Colon Cancer | — | Recruiting | — | — | — |
Show 2 more trialsShow fewer
NCT03732235CT.gov TACE Associated to Systemic Bevacizumab for the Treatment of Refractory Liver Metastases From Colorectal Cancer | — | Unknown | — | — | — |
NCT03069950CT.gov Study of Chemotherapy With or Without Hepatic Arterial Infusion for Patients With Unresectable Metastatic Colorectal Cancer to the Liver | — | Withdrawn | — | — | — |
Competitive Position
Competitive setting: how crowded the indication is, class-level failures, and timing against rivals.
89High confidence
Detailed axis rationale is planned and will be published soon.
Same indication · Metastasis From Malignant Tumor Of Colon
| Asset | Sponsor | Phase | Rating |
|---|---|---|---|
| Irinotecan (this asset) | Jun Huang | P3 | BB · 68 |
| Oxaliplatin | Fudan University | P4 | BBB |
| Fruquintinib | Peking University | P3 | BBB |
| Dexasone | Fudan University | P3 | BB |
| Capecitabine | Jun Huang | P3 | BB |
| Floxuridine | Fudan University | P3 | BB |
| Cetuximab | Shanghai 6th People's Hospital | P3 | BB |
| ip-001 | Immunophotonics, Inc. | P2/3 | BB |
| Panitumumab | University of Campania Luigi Vanvitelli | P2 | BB |
+42 more in the Metastasis From Malignant Tumor Of Colon cohort
Other indications for Irinotecan
| Indication | Sponsor | Phase | Rating |
|---|---|---|---|
| Rectal Cancer | — | P4 | BBB · 78 |
| Exocrine Pancreatic Carcinoma | — | P2/3 | BBB · 78 |
| Colon Adenocarcinoma | — | P3 | BBB · 76 |
Scientific Foundation
Strength of the underlying biology: target validation, tractability, modality fit, and how related mechanisms have fared.
NR
Planned for methodology v0.2.
Development Feasibility
How realistically the program can be executed, drawing on modality precedent, enrollment dynamics, and sponsor delivery.
NR
Planned for methodology v0.2.
Commercial Opportunity
Commercial prize: addressable population, unmet need, and the value case for the indication.
NR
Planned for methodology v0.2.
IP & Exclusivity
Exclusivity position, covering patent protection and freedom-to-operate runway.
NR
Planned for methodology v0.2.
Manufacturing & Supply
Manufacturing and supply readiness, driven by modality process and scale-up risk.
NR
Planned for methodology v0.2.
Citation
Floatz Terminal. Irinotecan in Metastasis From Malignant Tumor Of Colon. Methodology v0.2. Rated under v0.2 effective July 8, 2026. Last refreshed July 8, 2026. Accessed July 13, 2026. https://terminal.floatz.ai/assets/irinotecan-metastasis-from-malignant-tumor-of-colon
Are you the sponsor?
Submit your data room for a Verified Rating. The public-data rating remains visible alongside.
Contact →